Related Experiment Video
Updated: Sep 26, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Pneumococcal conjugate vaccines: proceedings from an interactive symposium at the 41st Interscience Conference on
Stephen I Pelton1, Ron Dagan, Beverly M Gaines
1Boston University School of Medicine, Boston Medical Center, Boston, MA, USA.
Insights
Pneumococcal conjugate vaccines, like the seven-valent formulation (PCV13), are crucial for preventing infant disease. Ongoing research tracks vaccine safety, effectiveness in vulnerable populations, and impact on antibiotic resistance.
Area of Science:
- Immunology
- Pediatrics
- Infectious Diseases
Background:
- Streptococcus pneumoniae causes significant infant illness globally.
- Antibiotic resistance necessitates vaccine development for prevention.
- The current seven-valent pneumococcal conjugate vaccine (PCV7) is widely used.
Framework:
- This paper summarizes a symposium on pneumococcal conjugate vaccines.
- Discussions included PCV7 safety, efficacy in premature infants, and impact on colonization.
- Evaluation of replacement disease, resistance rates, and updated recommendations were covered.
Implementation:
- Postmarketing surveillance of PCV7 safety.
- Clinical trials assessing vaccine impact in diverse infant populations.
- Analysis of direct and indirect effects on pneumococcal colonization and transmission.
Implications:
- Understanding PCV7's role in reducing disease burden and antibiotic resistance.
- Informing vaccination strategies and recommendations for infants and young children.
- Assessing the broader public health impact of conjugate vaccines in Europe and Asia-Pacific.
Abstract:
Globally, Streptococcus pneumoniae is a leading cause of invasive and noninvasive disease in infants and young children. The emergence of antibiotic-resistant strains has increased interest in prevention through immunization. Currently, the only available conjugate pneumococcal vaccine is a seven-valent formulation, PNCRM7. This paper presents excerpts from a symposium that provided an update of ongoing surveillance data and clinical trials evaluating pneumococcal conjugate vaccines. The topics addressed included: (1) PNCRM7 postmarketing safety data; (2) the impact of PNCRM7 in premature infants; (3) the direct and indirect effect of pneumococcal conjugate vaccines on colonization; (4) the effect of pneumococcal conjugate vaccines on replacement disease and the rate of resistance among replacement serotypes; (5) the current recommendations for the use of PNCRM7; and (6) the potential impact of conjugate vaccines in Europe and the Asia-Pacific region.
More Related Videos
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
13:47Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
Published on: May 19, 2020
Related Concept Videos
Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Atypical Pneumonia
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Streptococcal Pharyngitis
Antimicrobial Effectiveness